Tools
Ergotamine/Caffeine
Indications
Ergotamine has historically been used to treat migraine since the Middle Ages and has been available as a pharmaceutical since 1926, but its use is limited by poor tolerability (nausea, vomiting, and cardiovascular effects); thus, attempts were made to synthesize compounds with the same efficacy but improved safety. Researchers subsequently developed dihydroergotamine, but its use has substantially declined in contemporary practice, except for very specific indications.[1][2]
FDA-Approved Indications
Ergotamine/caffeine is approved by the US Food and Drug Administration (FDA) for aborting or preventing vascular headaches, including migraine and cluster headaches. Clinicians reserve ergotamine/caffeine for patients with moderate-to-severe attacks refractory to nonsteroidal anti-inflammatory drugs or combination analgesics, or for those with contraindications to triptans. Vasoconstrictive risks and medication-overuse potential limit the use of ergotamine/caffeine to 2 or fewer days per week and 10 mg or less per week. Clinicians should avoid ergotamine/caffeine in patients with cardiovascular disease or uncontrolled hypertension and in those taking strong cytochrome P450 3A4 (CYP3A4) inhibitors. Clinicians should consider calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) or selective serotonin 5-hydroxytryptamine-1F receptor agonists (ditans) for patients who have vascular risk factors or triptan intolerance.[3][4][5][6] Ergotamine has also been approved for cluster headache, previously termed as histaminic cephalalgia.[7][8] However, a systematic review indicates that clinicians use ergotamines less frequently and prefer triptans and oxygen therapy.[9][10]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Although the cause of migraine headaches is not entirely understood, arteriolar vasodilation and trigeminal nerve inflammation resulting from the release of local vasoactive peptides, such as 5-hydroxytryptamine (5-HT) and CGRP, play a role. CGRP is a neuropeptide found in the central and peripheral nervous systems and has both pain-signaling and vasodilator functions. Patients with migraines have elevated levels of circulating CGRP, and migraine medications, such as the ergot alkaloids, are associated with lowering these CGRP levels.[11][12] Ergotamine has a complex mechanism of action that involves multiple receptors, including 5-HT1B/1D, dopamine, and alpha-adrenergic receptors. By activating 5-HT1B and 5-HT1D receptors on intracranial blood vessels, ergotamine induces vasoconstriction, thereby relieving migraine headaches. At therapeutic doses, ergotamine also inhibits norepinephrine uptake and stimulates alpha-adrenergic receptors, resulting in prolonged vasoconstriction. Consequently, blood flow to the extremities is reduced.[13]
Caffeine may act synergistically with ergotamine by constricting cerebral vasculature and enhancing gastrointestinal absorption. The vasoconstrictive effects of caffeine are due to its antagonistic properties at adenosine A1, A2A, and A2B receptors. This highlights the role of adenosine receptors in mediating vasodilation. The mechanism of caffeine's rate-accelerating effect appears to stem from its ability to increase ergotamine's water solubility and decrease gastric pH. Caffeine also has numerous physiologic effects that may improve migraine symptoms, such as enhancing mood, alertness, and exercise performance.[14]
Pharmacokinetics
Absorption: After oral administration, ergotamine absorption is variable and incomplete due to extensive first-pass hepatic metabolism, with peak plasma concentrations occurring within 0.5 to 3 hours. Oral bioavailability is low.[15] Concomitant administration with caffeine increases the rate and extent of gastrointestinal absorption of ergotamine. This interaction increases systemic exposure and forms the basis for fixed ergotamine-caffeine formulations used in migraine therapy. After parenteral administration, systemic availability of ergotamine is rapid; intravenous (IV) administration provides complete systemic availability, and intramuscular (IM) administration results in rapid absorption with an absorption half-life of approximately 3 minutes.
Distribution: Ergotamine crosses the blood-brain barrier. Caffeine distributes widely throughout body water and readily crosses biologic membranes, including the blood-brain barrier and placenta.
Metabolism: Ergotamine undergoes extensive hepatic metabolism, primarily by the CYP3A4 enzyme system. Caffeine is metabolized almost completely in the liver, mainly by cytochrome P450 1A2 (CYP1A2).[16]
Excretion: Most ergotamine metabolites are excreted in bile and eliminated in feces, accounting for approximately 90% of the administered dose. Only small amounts are recovered in urine, with approximately 4% of an oral dose excreted unchanged. Caffeine metabolites are primarily excreted in urine, with approximately 1% to 2% excreted unchanged. The plasma elimination half-life of ergotamine is approximately 2 hours; however, pharmacokinetic studies demonstrate biphasic elimination, with an initial half-life of about 2.7 hours and a terminal phase of approximately 21 hours. The elimination half-life of caffeine in healthy adults is generally 3 to 7 hours, but it varies with cytochrome P450 1A2 activity.[PubChem]
Administration
Available Dosage Forms and Strengths
Ergotamine/caffeine is available as oral tablets (1 mg ergotamine + 100 mg caffeine), rectal suppositories (2 mg ergotamine + 100 mg caffeine), and 2 mg sublingual tablets; the aerosol formulation is no longer marketed.
Adult Dosage
Oral formulation: For slowly developing migraines without early nausea, oral or sublingual dosing is recommended; for severe, rapid-onset attacks with nausea or vomiting, the rectal suppositories are preferred. Initiate treatment at the first sign of attack, repeat once after 30 minutes if necessary, and limit to 6 mg per attack and 10 mg per week to reduce ergotism and medication-overuse risk.[17][18][19]
Sublingual formulation: Patients should place a 2-mg tablet under the tongue. Another tablet should be taken at half-hour intervals thereafter, if necessary, but dosage must not exceed 3 tablets in any 24 hours. The total weekly dosage should not exceed 5 tablets (10 mg).
Rectal suppository: The dose should be started at the first sign of an attack. The maximum dose for a single attack is 2 suppositories. Ergotamine/caffeine suppositories should not be used for chronic daily administration. Total weekly dosage should not exceed 5 suppositories.
According to the 2025 American Headache Society guidelines, evidence for subcutaneous ergotamine is classified as level U, and no recommendation can be made for its use in the emergency department setting. Subcutaneous ergotamine (0.5 mg) requires higher-quality, emergency department–specific acute treatment trials comparing it with a placebo or an active comparator to achieve level A evidence.[20]
Specific Patient Populations
Hepatic impairment: According to the product labeling, ergotamine is contraindicated in patients with hepatic impairment.
Renal impairment: Ergotamine is contraindicated in patients with renal impairment.
Pregnancy considerations: Ergotamine is contraindicated during labor and delivery because of its oxytocic effects, which are most pronounced in the third trimester.
Breastfeeding considerations: Ergotamine inhibits prolactin; however, its combination with caffeine has not been reported to reduce lactation. Ergotamine is excreted in breast milk and can potentially cause vomiting, diarrhea, weak pulse, and unstable blood pressure in infants. Given the risk of serious adverse effects, clinicians should carefully consider the risks and benefits when deciding whether to discontinue nursing or the medication. Current literature considers ergotamine to be contraindicated during breastfeeding.[21][22]
Pediatric patients: The safety and efficacy of ergotamine/caffeine have not been established in this population.
Older patients: According to the American Geriatrics Society Beers Criteria, ergot alkaloids should be avoided in older adults.[23]
Adverse Effects
Because ergotamine is not specific for the 5-HT1 serotonin receptors, it may cause a broad range of adverse effects. A common adverse effect of ergotamine/caffeine use is nausea and vomiting after both oral and parenteral administration, most likely due to a direct impact on central nervous system emetic centers. Cramps, insomnia, and transient lower-limb muscle pain may also occur. Other adverse effects of ergotamine tartrate associated with excessive dosage or chronic usage include ischemia, overuse headache, acroparesthesia, and ergotism.[24] Bocchia et al reported a case of chronic intoxication (ergotism), similar to the effects of ingesting Claviceps purpurea-infected rye, after ergotamine tartrate administration. The patient received rectal ergotamine for chronic migraine and showed signs of cerebral and leg ischemia due to vasospasm of the carotid and femoral arteries. Discontinuation of the drug resulted in complete remission of the symptoms.[25] Aabech et al also reported 14 cases of severe extremity ischemia attributable to ergotism.[26] Ergotamine-induced rectal lesions, though rare, may complicate therapy and warrant alternative routes of administration if long-term ergotamine use is anticipated.[27] Reports also describe myocardial infarction and fibrotic changes as adverse effects.[28] Perez et al reported a case of a patient with an ST-segment elevation myocardial infarction due to chronic ergotamine use, although such events are very rare.[29] Rectal ulcers and anorectal strictures have been reported with suppository overuse.[30]
Drug-Drug Interactions
CYP3A4 inhibitors: A case report indicates that chronic ergotamine use combined with itraconazole may cause severe upper-extremity ischemia due to CYP3A4 inhibition. In the report, discontinuation of ergotamine, along with thrombolysis and anticoagulation, reversed vasospasm and restored distal blood flow.[31] Please refer to the Contraindications and Box Warnings section for more information on additional interactions.
Vasoconstrictors: Ergotamine tartrate and caffeine should not be administered with other vasoconstrictors because of the risk of additive vasoconstrictive effects.
Sympathomimetic drugs: Concomitant use of ergotamine tartrate and caffeine with sympathomimetic pressor drugs may cause marked elevation of blood pressure.
Nicotine: Nicotine may provoke vasoconstriction in some patients, increasing the risk of ischemic response during ergot therapy.
Propranolol: Beta-adrenergic blockers such as propranolol have been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine by blocking the vasodilatory effect of epinephrine.[32]
Contraindications
Ergotamine tartrate/caffeine is contraindicated in patients with peripheral vascular disorders, coronary artery disease, stroke, uncontrolled hypertension, impaired renal or hepatic function, sepsis, and pregnancy due to its vasoconstrictive effects. Additionally, because ergotamine is metabolized via CYP3A4 in the liver, it is contraindicated in patients receiving CYP3A4 inhibitors, as these agents inhibit metabolism and may cause toxic effects, including stroke, gangrene, or death. Such CYP3A4 inhibitors include grapefruit juice, heparin, tacrolimus, cyclosporine, ampicillin, macrolide antibiotics, antifungals, protease inhibitors, and antidepressants.[33][34]
Box Warnings
Coadministration of ergotamine tartrate and caffeine with potent CYP3A4 inhibitors, such as protease inhibitors and macrolide antibiotics, can cause serious and potentially life-threatening peripheral ischemia.[35] Inhibition of CYP3A4 increases serum levels of ergotamine tartrate and caffeine, thereby elevating the risk of vasospasm, which can lead to cerebral and peripheral ischemia. Therefore, concomitant use of these medications is contraindicated.[33][36]
Warnings and Precautions
Ergotamine use has been associated with multisystem fibrosis, including fibrotic valvular heart disease.[37] Pleural, pericardial, and retroperitoneal fibrosis have also been reported.[38][39]
Monitoring
The bioavailability of ergotamine/caffeine is approximately 5% or less when administered orally or rectally. One study estimated the maximal bioavailability of 2% for tablets and 5% for suppositories.[40] Ergotamine/caffeine has an elimination half-life of 2 to 2.5 hours and a clearance of approximately 0.68 L/h/kg. Ergotamine/caffeine is administered initially as a 2-mg dose; if symptoms persist, 1 to 2 mg may be given every 30 minutes. However, limit the maximum dosage to 6 mg per attack and 10 mg per week as discussed earlier.[17]
Ergotamine/caffeine has been associated with misuse and psychological dependence.[41] Because vascular headaches are often chronic, clinicians should counsel patients to avoid exceeding the recommended dose or duration of therapy to minimize the risk of ergotism.
Baseline vital signs, including blood pressure, should be obtained. Patients should be monitored for signs of peripheral ischemia, such as vasospasm and cyanosis. Periodic monitoring of serum creatinine, blood urea nitrogen, and liver function tests may be required in patients with preexisting impairment.[17]
Toxicity
Signs and Symptoms of Overdose
Ergotamine poisoning and overdose symptoms are rarely observed in current clinical practice because newer, safer antimigraine agents such as triptans are more widely used owing to fewer adverse effects. However, intoxication symptoms may still occur in sensitive patients receiving ergotamine for migraine relief. Symptoms of overdose may include vomiting, paresthesia, and cyanosis of the extremities, often associated with diminished or absent peripheral pulses and lower-extremity ischemia.[42] Patients may also present with hypertension or hypotension, altered mental status, convulsions, and coma. A 5-year retrospective cross-sectional study (2014–2018) using the National Poison Data System (NPDS) evaluated exposures involving ergotamine and other antimigraine medications. A total of 1489 cases were identified, with most exposures involving multiple substances. The mean age was approximately 31 years, and the majority of patients were female. Major clinical effects from single-agent exposure were rare, and no deaths were reported. Ergotamine exposure most commonly caused abdominal pain, vomiting, numbness, nausea, diarrhea, and vertigo. Overall, severe toxicity was uncommon, although the risk increased with older age and multiple substance exposure.[43]
Management of Overdose
There is no antidote for ergotamine poisoning. Treatment involves discontinuation of the drug, which may relieve symptoms. One study reported that IV sodium nitroprusside, combined with low-molecular-weight dextran and heparin, was effective in treating ergotamine poisoning.[44][25]
Enhancing Healthcare Team Outcomes
A multidisciplinary approach to headache treatment improves patient care by employing strategies that treat pain and educate patients on self-management to enhance quality of life. Pharmacists, neurologists, psychologists, physical therapists, and primary care providers all play critical roles in managing headaches and reducing the risk of medication overuse headache.[45] Pharmacotherapy may be acute or preventive, and prescribers should remain aware of potential adverse drug reactions of ergotamine, as well as interactions with other agents, including CYP3A4 inhibitors. With the introduction of more selective drugs with improved tolerability, such as triptans and newer CGRP receptor antagonists, clinicians should exercise sound judgment and maintain effective communication within the healthcare team to evaluate medication options. Numerous studies have compared the efficacy and safety of triptans versus ergot alkaloids for acute migraine treatment, yielding mixed conclusions and highlighting the importance of individualized therapy and pharmacist consultation.[46][47][48][49]
Psychologists provide education, cognitive behavioral therapy, and self-management strategies for patients with migraine, addressing medication adherence, stress management, and lifestyle modifications. Physical therapists contribute to preventing headache episodes, particularly when neck or other musculoskeletal pain coexists. Additionally, relaxation techniques, biofeedback, and mindfulness-based stress reduction have demonstrated efficacy in migraine prevention.[50]
In suspected ergotamine toxicity or overdose, the emergency physician recognizes signs of vasospasm or limb ischemia, discontinues ergotamine immediately, and initiates vascular evaluation. Nurse practitioners or physician assistants perform rapid medication reconciliation and focused perfusion assessment, and communicate key findings using structured handoff methods such as the Situation, Background, Assessment, and Recommendation (SBAR) approach.[51] Clinical pharmacists identify high-risk drug interactions, particularly those involving CYP3A4 inhibitors, confirm the dosing history, and advise discontinuation of interacting medications. Nursing staff continuously monitor pulses, limb temperature, neurologic status, and vital signs while using closed-loop communication to confirm critical orders. Radiology or vascular specialists perform Doppler ultrasonography or angiography to detect vasospasm or arterial occlusion and guide further intervention. After stabilization, neurologists evaluate the patient and recommend safer migraine treatment alternatives to prevent recurrence.[52]
Given the chronic and multifactorial nature of migraine, an interprofessional and multidisciplinary approach integrating pharmacologic, behavioral, and physical strategies is essential for optimizing outcomes and improving patients' quality of life.[53][54][55][56]
References
Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - Then and Now: A Narrative Review. Headache. 2020 Jan:60(1):40-57. doi: 10.1111/head.13700. Epub 2019 Nov 17 [PubMed PMID: 31737909]
Level 3 (low-level) evidenceMonteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Current treatment options in neurology. 2011 Feb:13(1):1-14. doi: 10.1007/s11940-010-0105-6. Epub [PubMed PMID: 21110235]
Whealy M, Becker WJ. The 5-HT(1B) and 5-HT(1D) agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans. Handbook of clinical neurology. 2024:199():17-42. doi: 10.1016/B978-0-12-823357-3.00008-2. Epub [PubMed PMID: 38307644]
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15:325(23):2357-2369. doi: 10.1001/jama.2021.7939. Epub [PubMed PMID: 34128998]
Level 1 (high-level) evidenceGryglas-Dworak A, Schim J, Ettrup A, Boserup LP, Josiassen MK, Ranc K, Sperling B, Ashina M. Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial. Headache. 2025 Jan:65(1):101-112. doi: 10.1111/head.14862. Epub 2024 Nov 5 [PubMed PMID: 39501727]
Level 1 (high-level) evidenceShakir I, Shahzad F, Shabbir A, Shahabuddin S, Shabbir H, Karamat S, Hulou S, Khalid AR, Ahmed SI. Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis. European journal of clinical pharmacology. 2026 Jan 17:82(2):27. doi: 10.1007/s00228-025-03934-3. Epub 2026 Jan 17 [PubMed PMID: 41546694]
Level 1 (high-level) evidenceFanciullacci M. When cluster headache was called histaminic cephalalgia (Horton's headache). The journal of headache and pain. 2006 Sep:7(4):231-4 [PubMed PMID: 16767533]
Pellesi L, Mohammad A, Wang W, Martelletti P. Neurotransmitter Imbalance in Cluster Headache: A Systematic Review of Mechanisms and Therapeutic Targets. Pain and therapy. 2025 Dec:14(6):1629-1645. doi: 10.1007/s40122-025-00778-8. Epub 2025 Sep 19 [PubMed PMID: 40971112]
Level 1 (high-level) evidenceLaw S, Derry S, Moore RA. Triptans for acute cluster headache. The Cochrane database of systematic reviews. 2010 Apr 14:(4):CD008042. doi: 10.1002/14651858.CD008042.pub2. Epub 2010 Apr 14 [PubMed PMID: 20393964]
Level 1 (high-level) evidenceVan Obberghen EK, Fabre R, Bailly L, Lanteri-Minet M. Trends in the real-world management of cluster headache patients treated by subcutaneous sumatriptan and/or oxygen in France - An analysis of the French National Social Security System Open Data over eleven years (2014-2024). Revue neurologique. 2026 Jan-Feb:182(1-2):75-81. doi: 10.1016/j.neurol.2025.11.004. Epub 2025 Dec 16 [PubMed PMID: 41407575]
Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. The journal of headache and pain. 2017 Dec:18(1):42. doi: 10.1186/s10194-017-0750-1. Epub 2017 Apr 7 [PubMed PMID: 28389966]
Level 1 (high-level) evidenceRushendran R, Vellapandian C. Advances in Migraine Treatment: A Comprehensive Clinical Review. Current protein & peptide science. 2025:26(6):422-435. doi: 10.2174/0113892037329429241123095325. Epub [PubMed PMID: 39810518]
Level 3 (low-level) evidenceSilberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb:43(2):144-66 [PubMed PMID: 12558771]
Level 3 (low-level) evidenceAnderson JR, Drehsen G, Pitman IH. Effect of caffeine on ergotamine absorption from rat small intestine. Journal of pharmaceutical sciences. 1981 Jun:70(6):651-7 [PubMed PMID: 7252810]
Level 3 (low-level) evidenceTanna V, Sawarkar SP, Ravikumar P. Exploring Nose to Brain Nano Delivery for Effective Management of Migraine. Current drug delivery. 2023:20(2):144-157. doi: 10.2174/1567201819666220401091632. Epub [PubMed PMID: 35366772]
Mahdavi S, Palatini P, El-Sohemy A. CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction. JAMA network open. 2023 Jan 3:6(1):e2247868. doi: 10.1001/jamanetworkopen.2022.47868. Epub 2023 Jan 3 [PubMed PMID: 36701157]
. Ergot Alkaloids. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643724]
Mathew NT. Dosing and administration of ergotamine tartrate and dihydroergotamine. Headache. 1997:37 Suppl 1():S26-32 [PubMed PMID: 9009471]
Ekbom K, Krabbe AE, Paalzow G, Paalzow L, Tfelt-Hansen P, Waldenlind E. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. Cephalalgia : an international journal of headache. 1983 Mar:3(1):15-20 [PubMed PMID: 6406071]
Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2026 Jan:66(1):53-76. doi: 10.1111/head.70016. Epub 2025 Dec 1 [PubMed PMID: 41321235]
. Ergotamine. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000392]
Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. European journal of clinical pharmacology. 2014 Nov:70(11):1313-24. doi: 10.1007/s00228-014-1748-0. Epub 2014 Sep 13 [PubMed PMID: 25217187]
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023 Jul:71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4 [PubMed PMID: 37139824]
Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997:37 Suppl 1():S33-41 [PubMed PMID: 9009472]
Level 3 (low-level) evidenceBocchia M, Baldini GG, Bertola G, Zorzoli C. [Risks related to the use of ergotamine in the therapy of hemicrania. Description of a case]. Recenti progressi in medicina. 1991 Jul-Aug:82(7-8):390-3 [PubMed PMID: 1947404]
Level 3 (low-level) evidenceAabech J, Jensen FB, Engell HC. [Ergotism in migraine. Peripheral vascular complications in 14 patients with migraine]. Ugeskrift for laeger. 1989 Aug 14:151(33):2067-70 [PubMed PMID: 2773132]
Level 3 (low-level) evidenceJost WH, Schimrigk K. [Ergotamine-induced rectal lesions in asymptomatic patients]. Wiener klinische Wochenschrift. 1994:106(6):171-3 [PubMed PMID: 8197748]
Meyler WJ. Side effects of ergotamine. Cephalalgia : an international journal of headache. 1996 Feb:16(1):5-10 [PubMed PMID: 8825693]
Pérez Baztarrica GE, Armijos Carrion LP, Abarca Real JH, Paredes Lima WA, Giler Saltos OP, Porcile R. Acute coronary syndrome with elevation of ST associated with ergotamine abuse. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2019 Mar 1:57(1):69-71. doi: 10.2478/rjim-2018-0023. Epub [PubMed PMID: 30954974]
Sayfan J. Ergotamine-induced anorectal strictures: report of five cases. Diseases of the colon and rectum. 2002 Feb:45(2):271-2 [PubMed PMID: 11852344]
Level 3 (low-level) evidenceCervi E, Bonardelli S, Battaglia G, Gheza F, Maffeis R, Nodari F, Maroldi R, Giulini SM. Upper limb artery segmental occlusions due to chronic use of ergotamine combined with itraconazole, treated by thrombolysis. Thrombosis journal. 2011 Aug 30:9():13. doi: 10.1186/1477-9560-9-13. Epub 2011 Aug 30 [PubMed PMID: 21878097]
Baumrucker JF. Drug interaction--propranolol and cafergot. The New England journal of medicine. 1973 Apr 26:288(17):916-7 [PubMed PMID: 4693950]
Wooltorton E. Risk of stroke, gangrene from ergot drug interactions. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2003 Apr 15:168(8):1015 [PubMed PMID: 12695387]
Wells KE, Steed DL, Zajko AB, Webster MW. Recognition and treatment of arterial insufficiency from cafergot. Journal of vascular surgery. 1986 Jul:4(1):8-15 [PubMed PMID: 3723691]
Level 3 (low-level) evidenceBaldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. Journal of vascular surgery. 2003 Mar:37(3):676-8 [PubMed PMID: 12618710]
Ayarragaray JE. Ergotism: a change of persepective. Annals of vascular surgery. 2014 Jan:28(1):265-8. doi: 10.1016/j.avsg.2013.02.005. Epub 2013 Aug 28 [PubMed PMID: 23992606]
Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet (London, England). 2009 Aug 15:374(9689):577-85. doi: 10.1016/S0140-6736(09)60252-X. Epub [PubMed PMID: 19683643]
Murad MH, Miller FA, Glockner J. Multi-system fibrosis and long-term use of ergotamine. Annals of the Academy of Medicine, Singapore. 2011 Jul:40(7):327-8 [PubMed PMID: 21870025]
Patra S, Padhi S, Padhan P, Kar M, Nayak P, Samal SC. Ergotamine Induced Retroperitoneal Fibrosis. Mediterranean journal of rheumatology. 2021 Jun:32(2):168-173. doi: 10.31138/mjr.32.2.168. Epub 2021 Jun 30 [PubMed PMID: 34447915]
Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. British journal of clinical pharmacology. 1983 Dec:16(6):695-9 [PubMed PMID: 6419759]
Nowak J, Woźniakiewicz M, Klepacki P, Sowa A, Kościelniak P. Identification and determination of ergot alkaloids in Morning Glory cultivars. Analytical and bioanalytical chemistry. 2016 May:408(12):3093-102. doi: 10.1007/s00216-016-9322-5. Epub 2016 Feb 12 [PubMed PMID: 26873205]
Garcia GD, Goff JM Jr, Hadro NC, O'donnell SD, Greatorex PS. Chronic ergot toxicity: A rare cause of lower extremity ischemia. Journal of vascular surgery. 2000 Jun:31(6):1245-7 [PubMed PMID: 10842162]
Robblee JV, Butterfield RJ, Kang AM, Smith JH. Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System. Neurology. 2020 Apr 7:94(14):e1460-e1469. doi: 10.1212/WNL.0000000000008685. Epub 2019 Dec 2 [PubMed PMID: 31792093]
Skowronski GA, Tronson MD, Parkin WG. Successful treatment of ergotamine poisoning with sodium nitroprusside. The Medical journal of Australia. 1979 Jul 14:2(1):8-9 [PubMed PMID: 502953]
Level 3 (low-level) evidenceNada MAF, Helmy MA, Zein MM, Hatem G. Medication overuse headache from a tertiary headache center in Egypt: real-world insights. The journal of headache and pain. 2026 Jan 24:27(1):30. doi: 10.1186/s10194-025-02263-1. Epub 2026 Jan 24 [PubMed PMID: 41580608]
Miljković S, Smajlović D, Tirić Campara M, Jurina R, Duranović Vinković L, Janković SM, Begović B, Ćeranić M. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan-Mar:22(1):17-22 [PubMed PMID: 31213753]
Level 2 (mid-level) evidenceDemaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P & T : a peer-reviewed journal for formulary management. 2008 Jul:33(7):404-16 [PubMed PMID: 19750119]
Level 3 (low-level) evidenceÖztürk V. Acute Treatment of Migraine. Noro psikiyatri arsivi. 2013 Aug:50(Suppl 1):S26-S29. doi: 10.4274/Npa.y7299. Epub 2013 Aug 1 [PubMed PMID: 28360580]
Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine - systematic review. The journal of headache and pain. 2024 Apr 5:25(1):51. doi: 10.1186/s10194-024-01753-y. Epub 2024 Apr 5 [PubMed PMID: 38575868]
Level 1 (high-level) evidenceTreadwell JR, Tsou AY, Rouse B, Ivlev I, Fricke J, Buse DC, Powers SW, Minen M, Szperka CL, Mull NK. Behavioral interventions for migraine prevention: A systematic review and meta-analysis. Headache. 2025 Apr:65(4):668-694. doi: 10.1111/head.14914. Epub 2025 Feb 19 [PubMed PMID: 39968795]
Level 1 (high-level) evidenceMüller M, Jürgens J, Redaèlli M, Klingberg K, Hautz WE, Stock S. Impact of the communication and patient hand-off tool SBAR on patient safety: a systematic review. BMJ open. 2018 Aug 23:8(8):e022202. doi: 10.1136/bmjopen-2018-022202. Epub 2018 Aug 23 [PubMed PMID: 30139905]
Level 1 (high-level) evidenceAguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Atencion primaria. 2022 Feb:54(2):102208. doi: 10.1016/j.aprim.2021.102208. Epub 2021 Nov 16 [PubMed PMID: 34798397]
Larsson B, Carlsson J, Fichtel A, Melin L. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache. 2005 Jun:45(6):692-704 [PubMed PMID: 15953302]
Level 1 (high-level) evidenceGaul C, Visscher CM, Bhola R, Sorbi MJ, Galli F, Rasmussen AV, Jensen R. Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. The journal of headache and pain. 2011 Oct:12(5):511-9. doi: 10.1007/s10194-011-0364-y. Epub 2011 Jul 21 [PubMed PMID: 21779789]
Tram J, Byl M, Davis A, Pham Q. Interdisciplinary Headache Management. Physical medicine and rehabilitation clinics of North America. 2025 Nov:36(4):825-837. doi: 10.1016/j.pmr.2025.07.008. Epub 2025 Sep 3 [PubMed PMID: 41167859]
Durand MJ, Coutu MF, Gérard T, Royer MP, Devantéry K, Godbout P, Laprise S, Leroux É, Paquette MA. Multidisciplinary Rehabilitation Intervention Activities for People with Migraine: Scoping Review. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2025 Jan 23:():1-10. doi: 10.1017/cjn.2025.5. Epub 2025 Jan 23 [PubMed PMID: 39844712]
Level 2 (mid-level) evidence